Navigation Links
Mentice AB Announces the Appointment of Lars Lonn as Clinical Director for Mentice
Date:3/28/2008

GOTHENBURG, Sweden, March 28 /PRNewswire/ -- Mentice AB, a leading supplier of virtual reality based training applications within the field of medicine has recently appointed Lars Lonn as Clinical Director for Mentice.

Professor Lonn, an Interventional Radiologist, is also a leading European professor within the field of Endovascular Surgery and a faculty member of Rigshospital Health Sciences in Copenhagen, Denmark.

Professor Lonn recently completed a study with Max Berry, MD, Mikael Hellstrom, MD, Jan Gothlin, MD, and Richard Reznick, MD, MEd, FRCSC, which was featured in the Journal of Vascular Interventional Radiology entitled, "Endovascular Training with Animals versus Virtual Reality Systems: An Economic Analysis."

Goran Malmberg, CEO and President of Mentice said, "This is a monumental step forward for us. Professor Lonn will have a vital role with Mentice verifying the direction of our product development, while increasing the awareness and need for training solutions in healthcare. In the long run, we feel that Clinical Directors will play a vital role in driving medical training through the use of medical simulation."

About Mentice:

Mentice is a leader in medical simulation with approximately 600 installations worldwide, 100 validation studies and more than 30 issued and pending patents. Mentice's Family of Procedicus (TM) simulators focus on the area of minimally invasive surgery within the fields of endovascular intervention, core skills training, laparoscopy and arthroscopy training.

Website info: http://www.mentice.com

For more information contact: Goran Malmberg at +46 31 33 99 401 (Gothenburg office) or email, goran.malmberg@mentice.com.

Release #32808


'/>"/>
SOURCE Mentice Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Mentice AB Announces Leadership Changes Within Its Worldwide Operations
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)("Interpace" ... useful molecular diagnostic tests and pathology services, today ... purchase agreement with three  institutional investors to purchase ... in a registered direct offering.  In a concurrent ... to the same investors warrants to purchase 855,000 ...
(Date:1/21/2017)... Jan. 20, 2017 Aratana Therapeutics, Inc. (NASDAQ: ... on the licensing, development and commercialization of innovative biopharmaceutical ... Best Company in North America ... award based on the FDA approval of three ... ENTYCE ® (capromorelin oral solution) and NOCITA ® ...
(Date:1/20/2017)... , ... January 20, 2017 , ... The two newest ... treatment options for patients. Vironika, a spin out from The Wistar Institute, and Sanguis, ... lab space at 3624 Market Street. , Vironika is developing a treatment for ...
(Date:1/20/2017)... , Jan. 20, 2017 Ginkgo ... of Gen9, a pioneer in the synthesis and ... unique expertise in assembling pathway-length synthetic DNA into ... and capacity in the construction of new organism ... industries. "Gen9 was founded to significantly ...
Breaking Biology Technology:
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a leading ... the release of its patent-pending calibration device. With this ... perform calibrations, securely upload data logs and process repairs ... customer. "Fighting drunk driving through the application ... public at large, but also for the customer who ...
(Date:1/6/2017)... Jan. 6, 2017  Privately-held CalciMedica, Inc., announced ... healthy volunteers of a novel calcium release-activated calcium ... pancreatitis. Acute pancreatitis, sudden painful ... disorder, but can be very serious.  In severe cases ... where extended hospital stays, time in the ICU ...
(Date:1/6/2017)... 5, 2017  Delta ID Inc., a leader in ... for automotive at CES® 2017. Delta ID has collaborated ... demonstrate the use of iris scanning as a secure, ... driver in a car, and as a way to ... Delta ID and Gentex will demonstrate (booth ...
Breaking Biology News(10 mins):